Cargando…

Dostarlimab, a boon or a healthcare burden- too early to acertain!

Detalles Bibliográficos
Autores principales:	Fatima, Nabeela, Tabbasum, Nashra, Mandava, Kiranmai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289427/ https://www.ncbi.nlm.nih.gov/pubmed/35860069 http://dx.doi.org/10.1016/j.amsu.2022.104050

Ejemplares similares

Monkeypox- a menacing challenge or an endemic?
por: Fatima, Nabeela, et al.
Publicado: (2022)

Dostarlimab: A breakthrough in the field of oncology
por: Hussain, Hassan ul, et al.
Publicado: (2022)

Jemperli (Dostarlimab-gxly): An unprecedented cancer trial
por: Ali, Eman, et al.
Publicado: (2022)

Dostarlimab: A Review
por: Costa, Bárbara, et al.
Publicado: (2022)

Coronavirus disease and basic sanitation: too early to be worried?
por: da Silva, Renata Rocha, et al.
Publicado: (2020)

An Integrated Analysis of Dostarlimab Immunogenicity
por: Lu, Sharon, et al.
Publicado: (2021)

Ventilators in ICU: A boon or burden
por: Mehndiratta, Man Mohan, et al.
Publicado: (2016)

Radiology in the Undergraduate Medical Curriculum: Too Little, Too Late?
por: Dmytriw, Adam A., et al.
Publicado: (2015)

Early Treatment of Class III Malocclusion: A Boon or a Burden?
por: Begum Khan, Mohammadi, et al.
Publicado: (2014)

A transplant compatible with all patients: A salvage underway
por: Srikaram, Prakhyath, et al.
Publicado: (2022)

CLInical Profile and Side Effects of chronic use of oral Amiodarone in cardiology outpatients department (CLIPSE-A Study)- A prospective observational study
por: Fatima, Nabeela, et al.
Publicado: (2022)

Dostarlimab/tozinameran: Various toxicities: case report
Publicado: (2022)

Dostarlimab: The miracle drug for the treatment of colorectal cancer
por: Shuvo, Pollob Ahmed, et al.
Publicado: (2022)

Lung ultrasound: are we diagnosing too much?
por: Volpicelli, Giovanni, et al.
Publicado: (2023)

Mobile technology: A tool for healthcare and a boon in pandemic
por: Sharma, Sadhana, et al.
Publicado: (2022)

Dementia Still Diagnosed Too Late — Data from the Czech Republic
por: LUZNY, Jan, et al.
Publicado: (2014)

Dostarlimab: From preclinical investigation to drug approval and future directions
por: Cicala, Carlo Maria, et al.
Publicado: (2023)

Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment
por: Singh, Vanshikha, et al.
Publicado: (2022)

Boone & Kurtz : marketing contemporáneo /
por: Kurtz, David L.
Publicado: (2012)

Are the Recommended Excision Margins for Basal Cell Carcinoma Too Defensive? A Retrospective Chart Study and Evaluation of the Dutch Guideline
por: VAN LOO, Eva, et al.
Publicado: (2021)

Selfies: A boon or bane?
por: Bansal, Agam, et al.
Publicado: (2018)

Immune checkpoint inhibitor-induced encephalitis with dostarlimab in two patients: Case series
por: Marzoughi, Sina, et al.
Publicado: (2021)

Early severe HIV disease precedes early antiretroviral therapy in infants: Are we too late?
por: Innes, Steve, et al.
Publicado: (2014)

Cystatin C as a Candidate Biomarker of Cardiovascular Outcomes: Too Near, but too Far from Reality
por: de Carvalho, Luiz Sérgio F., et al.
Publicado: (2018)

The devastating effect of cyclone Freddy amidst the deadliest cholera outbreak in Malawi: a double burden for an already weak healthcare system—short communication
por: Focus Adriano, Lubanga, et al.
Publicado: (2023)

Too short and too poor: A tale of two siblings
por: Balaji, Laxminarasimhan, et al.
Publicado: (2012)

Severe scalds sustained during steam inhalation therapy in an adult population: Analysis of patient outcomes and the financial burden to healthcare services
por: Dearden, Alexander S., et al.
Publicado: (2022)

A boon to aged society: Early diagnosis of Alzheimer's disease–An opinion
por: Francis, Ambily, et al.
Publicado: (2022)

Blood pressure-lowering and cardiovascular effects of plumbagin in rats: An insight into the underlying mechanisms
por: Ahmad, Maira, et al.
Publicado: (2022)

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
por: Mathews, Cara, et al.
Publicado: (2022)

Precision Attachment Boon to Prosthodontists
por: Ghiaz, Khalid, et al.
Publicado: (2022)

Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
por: Alkholifi, Faisal K., et al.
Publicado: (2022)

Patient Education: Boon or Bane?
por: Sohoni, Chandrashekhar A.
Publicado: (2013)

Antipsychotics and OCD: Boon or Bane?
por: Naguy, Ahmed
Publicado: (2017)

Ketogenic diets: Boon or bane?
por: Shilpa, Joshi, et al.
Publicado: (2018)

Low vision aids: A boon
por: Natarajan, Sundaram
Publicado: (2013)

Probiotics in dentistry: A boon or sham
por: Chopra, Rahul, et al.
Publicado: (2013)

Long Hairs: Boon or a Bane?
por: Yesudian, Patrick
Publicado: (2012)

CBCT imaging – A boon to orthodontics
por: Machado, Genevive L.
Publicado: (2014)

Yoga: A boon for the dental professionals
por: Kapoor, Vinod
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gv07iprs1jekti36sslfdp1256